Igenomix portfolio includes pioneering genetic tests to help reproductive-health professionals to analyse and treat their patients before, during and after their reproductive journey.
Vitrolife delivers innovative, high-quality products to ensure optimal care at every stage of the IVF journey, from error prevention and gamete handling to embryo evaluation and cryopreservation.
For decades of innovation, we have made a difference
Our passion and commitment to making a difference in reproductive health has never been more dedicated.
Discover our values through the voices of those within the Vitrolife Group.
Latest financial report
Fourth quarter and full year report, 2024: A strong finish to the year
In summary, 2024 was a year of record revenue in Consumables and Technologies. We delivered accelerated growth, EBITDA expansion and strong cash flow.
Press Releases
Financial Calendar
-
27 Mar 2025
Annual and sustainability report 2024
-
24 Apr 2025
Interim report Q1, 2025
-
29 Apr 2025
Annual General Meeting 2025
Careers
The Vitrolife Group offers an attractive workplace with an opportunity to work for a higher purpose, a purpose that makes a difference in people’s lives worldwide.
Investor relations
Our aim is to have a strong capital base to enable continued high growth, both organically and through acquisitions. We strive to achieve growth through profitability.
Sustainability
Ensuring sustainability in everything we do is one of our key strategic priorities. Learn more on our approach and sustainability themes.